Slide 1: Acrux Investor Presentation and Full Year Results
ACRUX INVESTOR PRESENTATION AND FULL YEAR RESULTS (ASX: ACR) August 2019
Slide 2: Investment Highlights
INVESTMENT HIGHLIGHTS Attractive and • The topical generic market provides attractive returns with fast, low-risk development costs for accessible highly specialised drug developers market • The size of the topical generic market in the US alone worth ~US$20bn Focus on • Acrux is deliberately focusi
Slide 3: Acrux has achieved key milestones in FY19, performing strongly against set objectives
ACRUX HAS ACHIEVED KEY MILESTONES IN FY19, PERFORMING STRONGLY AGAINST SET OBJECTIVES FY19 Acrux Submit 2 objectives dossiers to FDA Scale up 6 projects Add further from Acrux laboratory products to generic (in addition to FY18 to CMOs portfolio submission) ▪ 1 dossier submitted in FY18 Product port
Slide 4: Acrux has clear objectives in the near term as the company seeks to continue its progress
ACRUX HAS CLEAR OBJECTIVES IN THE NEAR TERM AS THE COMPANY SEEKS TO CONTINUE ITS PROGRESS CY19 CY20 Acrux objectives First revenues from Add further Execute licensing Have 4 additional generic portfolio in products to generic deals for products in dossiers accepted for CY19 portfolio pipeline review
Slide 5: Multiple advantages for generic prescription product development
MULTIPLE ADVANTAGES FOR GENERIC PRESCRIPTION PRODUCT DEVELOPMENT Traditional development Acrux’s generic development portfolio Market size A new drug may have a significant market Attractive market and licensee terms opportunity, however… Speed …it takes ~10+ years1 to develop a new drug, involving
Slide 6: Topical generics: an attractive US$20bn market
TOPICAL GENERICS: AN ATTRACTIVE US$20bn MARKET Acrux focus Total market Oral drugs Topical drugs Drugs that are applied topically Total US prescription Definition of market Drugs that are ingested orally (including directly to the skin, pharma market eyes, ears and nose) Market size1 >US$460bn ~US$2
Slide 7: Acrux has a focused strategy on drug selection and development
ACRUX HAS A FOCUSED STRATEGY ON DRUG SELECTION AND DEVELOPMENT An illustrative pathway for generic drug development and commercialisation Status Description Acrux expects a typical license agreement to Commercial LAUNCH CY19 discussions underway consist of an annuity-style revenue stream, with the p
Slide 8: Acrux is developing its product pipeline towards commercialisation
ACRUX IS DEVELOPING ITS PRODUCT PIPELINE TOWARDS COMMERCIALISATION Addressable market value of portfolio1 ($USm) # of commercialised generic (ANDA) Addressable market competitors approved and on the market2 5+ Generics US$1.5 bn 4 Generics Based on 14 products currently in the Acrux 3 Generics topic
Slide 9: Summary of product pipeline
SUMMARY OF PRODUCT PIPELINE 3 dossiers accepted for review 11 drugs in development Generic of Jublia® Testosterone Generic of topical solution topical solution EMLA® cream Market opportunity: US$1156m1 (for products in development phase pre regulatory submission) Date accepted August 2018 October 20
Slide 10: Experienced management team with a proven history of meeting operational milestones
EXPERIENCED MANAGEMENT TEAM WITH A PROVEN HISTORY OF MEETING OPERATIONAL MILESTONES Management team World class topical R&D team Michael Kotsanis, BSc, MBus “We have made significant progress over CEO & Managing Director the last 12 months in developing our topical Experienced leader in the pharmace
Slide 11: Strategic direction led by a board with highly relevant expertise
STRATEGIC DIRECTION LED BY A BOARD WITH HIGHLY RELEVANT EXPERTISE Michael Kotsanis Ross Dobinson CEO & Managing Director Non-Executive • Experienced leader in the pharmaceuticals industry with Chairman Palla Pharma demonstrated success commercialising generic products • Michael was formally the chie
Slide 12: Full Year Profit and Loss
FULL YEAR PROFIT AND LOSS Full Year Ending 30 June 2019 30 June 2018 #039;000 #039;000 % Royalty revenue 631 2,687 (76.5)% Interest & other income 579 671 (13.8)% Grant revenue 4,072 0 - Other income 4 74 (94.6)% Total 5,286 3,432 54.0% R&D investment (10,917) (10,624) 2.8% Other operating costs (2,189) (
Slide 13: Full Year Cashflow
FULL YEAR CASHFLOW Full Year Ending 30 June 2019 30 June 2018 #039;000 #039;000 % Cash flow from operating activities Receipts from product agreements 576 7,872 (92.7)% Payments to suppliers and employees (13,233) (12,731) 3.9% Interest received 611 610 0.2% Income tax refunded / (paid) 51 (1,033) (104.9)
Slide 14: Corporate Overview
CORPORATE OVERVIEW Trading Information Share price performance (last 12 months) Share price (A$) Volume (k) Share price (as at 23 August 2019) A$0.175 0.40 8,000 Shares outstanding1 166.7m 0.35 7,000 Market capitalisation A$29.1m 0.30 6,000 Cash (as at 30 June 2019) A$18.2m Implied enterprise value
Slide 15: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present
Slide 16: Thank You
THANK YOU Investor enquiries Michael Kotsanis Anthony England Acrux Limited Vesparum Capital CEO & Managing Director Director P: + 61 3 8379 0100 P: + 61 3 8582 4800 E: michael.kotsanis@acrux.com.au E: Acrux@vesparum.com Visit our website: http://www.acrux.com.au/ Follow us on LinkedIn: